会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • POLYMERIC CONJUGATES CONTAINING PHOSPHINE - BASED CHELATING GROUPS
    • 含聚磷酸酯基团的聚合物
    • WO2005011738A3
    • 2005-04-14
    • PCT/IT2004000422
    • 2004-07-29
    • UNIV PADOVAVERONESE FRANCESCOMAZZI ULDERICOPASUT GIANFRANCOVISENTIN ROBERTA
    • VERONESE FRANCESCOMAZZI ULDERICOPASUT GIANFRANCOVISENTIN ROBERTA
    • A61K47/48A61K49/12A61K51/06
    • A61K51/065A61K47/60A61K49/085A61K49/126
    • Reactive polymers can be conjugated, directly or by means of linkers and/or others polymers to chelating agents comprising at least one phosphorous atom in the form of a phosphine or phosphine oxide (or precursors thereof) to form conjugates useful in diagnostic and therapeutic applications. In particular this invention provides conjugates comprising a hydrophilic polymer bound, directly or by means of other moieties, to at least one chelating group able to chelate metal radioisotopes comprising at least one phosphine or one phosphine oxide phosphorous. Such chelating groups can be conjugated to the hydrophilic polymer directly or via one or more linkers and/or one or more additional polymers. The use of additional polymers can provide increased loading of chelating agent. The linkers are preferably selected among alkyl groups or aromatic groups or cleavable peptides or other biodegradable sequences. Additionally, one or more targeting molecules can be linked to the hydrophilic polymer directly or by means of linkers and/or others polymers. Due to their polymeric structure, the conjugates according to the invention have enhanced specificity toward certain tissues, such as tumors, inflamed tissued and the liver. The specificity can be further increased by the additional provision of targeting moieties such as antibodies or sugars. These conjugates can be formulated for remaining in the blood circulation for a period for time suitable for diagnostic and therapeutic applications. Moreover they possess thermodynamic and kinetic stability, keeping the metal chelate intact under physiological conditions. The invention also provides a very simple and efficient method for the labelling of radiopharmaceuticals, which avoids the use of any additional reducing agent. Accordingly, metal ions like technetium or rhenium can be added as pertechnetate or pherrhenate to chelating agents comprising polymer and a phosphine and surprisingly it has been found that such chelating agents can act as reducing agents of the metal and the use of an additional reducing agent is not necessary. This allows the preparation of simple kits comprising a component (a) comprising the polymeric chelating agent and a component (b) comprising the metal ion in its highest oxidation state. These two components can be kept separately and combined together just before use to yield the metal complex without the need of further reducing step and purification.
    • 反应性聚合物可以直接或通过接头和/或其它聚合物与螯合剂共轭,所述螯合剂包含至少一种磷化氢或氧化膦(或其前体)形式的磷原子,以形成可用于诊断和治疗应用的缀合物。 特别地,本发明提供了缀合物,其包含直接或通过其它部分结合至少一个能够螯合包含至少一个膦或一种氧化膦磷的金属放射性同位素的螯合基团的亲水性聚合物。 这样的螯合基团可以直接或通过一种或多种接头和/或一种或多种另外的聚合物与亲水性聚合物缀合。 使用另外的聚合物可以提供增加螯合剂的负载量。 连接体优选选自烷基或芳族基团或可切割肽或其它可生物降解的序列。 另外,一个或多个靶向分子可以直接或通过接头和/或其它聚合物与亲水性聚合物连接。 由于其聚合物结构,根据本发明的缀合物对某些组织(例如肿瘤,发炎组织和肝脏)具有增强的特异性。 可以通过额外提供靶向部分例如抗体或糖来进一步提高特异性。 这些缀合物可以配制用于在血液循环中保持一段适合诊断和治疗应用的时间。 此外,它们具有热力学和动力学稳定性,在生理条件下保持金属螯合物完整。 本发明还提供了用于放射性药物标记的非常简单和有效的方法,其避免使用任何另外的还原剂。 因此,可以将诸如锝或铼的金属离子作为高锝酸盐或苯乙烯酸盐加入到包含聚合物和膦的螯合剂中,并且令人惊讶地发现,这种螯合剂可以作为金属的还原剂,并且使用另外的还原剂是 不必要。 这允许制备包含包含聚合物螯合剂的组分(a)和包含其最高氧化态的金属离子的组分(b)的简单试剂盒。 这两种组分可以在使用前分开保存并组合在一起以产生金属络合物,而不需要进一步的还原步骤和纯化。
    • 8. 发明申请
    • POLYMERIC CONJUGATES FOR DIAGNOSIS AND THERAPY
    • 聚合物用于诊断和治疗
    • WO2005011738A2
    • 2005-02-10
    • PCT/IT2004/000422
    • 2004-07-29
    • UNIVERSITÀ DEGLI STUDI DI PADOVAVERONESE, FrancescoMAZZI, UldericoPASUT, GianfrancoVISENTIN, Roberta
    • VERONESE, FrancescoMAZZI, UldericoPASUT, GianfrancoVISENTIN, Roberta
    • A61K47/00
    • A61K51/065A61K47/60A61K49/085A61K49/126
    • Reactive polymers can be conjugated, directly or by means of linkers and/or others polymers to chelating agents comprising at least one phosphorous atom in the form of a phosphine or phosphine oxide (or precursors thereof) to form conjugates useful in diagnostic and therapeutic applications. In particular this invention provides conjugates comprising a hydrophilic polymer bound, directly or by means of other moieties, to at least one chelating group able to chelate metal radioisotopes comprising at least one phosphine or one phosphine oxide phosphorous. Such chelating groups can be conjugated to the hydrophilic polymer directly or via one or more linkers and/or one or more additional polymers. The use of additional polymers can provide increased loading of chelating agent. The linkers are preferably selected among alkyl groups or aromatic groups or cleavable peptides or other biodegradable sequences. Additionally, one or more targeting molecules can be linked to the hydrophilic polymer directly or by means of linkers and/or others polymers. Due to their polymeric structure, the conjugates according to the invention have enhanced specificity toward certain tissues, such as tumors, inflamed tissued and the liver. The specificity can be further increased by the additional provision of targeting moieties such as antibodies or sugars. These conjugates can be formulated for remaining in the blood circulation for a period for time suitable for diagnostic and therapeutic applications. Moreover they possess thermodynamic and kinetic stability, keeping the metal chelate intact under physiological conditions. The invention also provides a very simple and efficient method for the labelling of radiopharmaceuticals, which avoids the use of any additional reducing agent. Accordingly, metal ions like technetium or rhenium can be added as pertechnetate or pherrhenate to chelating agents comprising polymer and a phosphine and surprisingly it has been found that such chelating agents can act as reducing agents of the metal and the use of an additional reducing agent is not necessary. This allows the preparation of simple kits comprising a component (a) comprising the polymeric chelating agent and a component (b) comprising the metal ion in its highest oxidation state. These two components can be kept separately and combined together just before use to yield the metal complex without the need of further reducing step and purification.
    • 反应性聚合物可以直接或通过接头和/或其它聚合物与螯合剂共轭,所述螯合剂包含至少一种磷化氢或氧化膦(或其前体)形式的磷原子以形成用于诊断和治疗应用的缀合物。 特别地,本发明提供了包含直接或通过其它部分结合至少一个能够螯合包含至少一个膦或一种氧化膦磷的金属放射性同位素的至少一种螯合基团的亲水性聚合物的缀合物。 这样的螯合基团可以直接或通过一种或多种接头和/或一种或多种另外的聚合物与亲水聚合物缀合。 使用额外的聚合物可以提供增加螯合剂的负载量。 连接体优选选自烷基或芳族基团或可切割肽或其它可生物降解的序列。 另外,一个或多个靶向分子可以直接或通过接头和/或其它聚合物与亲水性聚合物连接。 由于其聚合物结构,根据本发明的缀合物对某些组织(例如肿瘤,发炎组织和肝脏)具有增强的特异性。 可以通过额外提供靶向部分例如抗体或糖来进一步提高特异性。 这些缀合物可以配制用于在血液循环中保持一段适合于诊断和治疗应用的时间。 此外,它们具有热力学和动力学稳定性,在生理条件下保持金属螯合物完整。 本发明还提供了一种用于标记放射性药物的非常简单和有效的方法,其避免使用任何另外的还原剂。 因此,可以将诸如锝或铼的金属离子作为高锝酸盐或苯乙烯酸酯加入到包含聚合物和膦的螯合剂中,并且令人惊讶地发现,这种螯合剂可以用作金属的还原剂,并且使用另外的还原剂是 不必要。 这允许制备包含包含聚合物螯合剂的组分(a)和包含其最高氧化态的金属离子的组分(b)的简单试剂盒。 这两种组分可以在使用前分开保存并组合在一起以产生金属络合物,而不需要进一步的还原步骤和纯化。